Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Pinterest, Inc. and its officers or directors, following a significant restructuring announcement by the company [1][3]. Group 1: Company Actions - On January 27, 2026, Pinterest announced a global restructuring plan that includes a workforce reduction affecting less than 15% of its employees and a reduction in office space [3]. - The company anticipates incurring pre-tax restructuring charges of approximately $35 million to $45 million, primarily in cash-related expenditures [3]. - The restructuring aims to support transformation initiatives focused on reallocating resources to AI roles, prioritizing AI-powered products, and accelerating changes in sales and marketing strategies [3]. Group 2: Market Reaction - Following the announcement of the restructuring plan, Pinterest's stock price fell by $2.49 per share, or 9.61%, closing at $23.41 per share on January 27, 2026 [3].

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of PayPal Holdings, Inc. (“PayPal” or the “Company”) (NASDAQ: PYPL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether PayPal and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On February 3 ...

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against PomDoctor Ltd. (“PomDoctor” or the “Company”) (NASDAQ: POM).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether PomDoctor and certain of its ...

SAN FRANCISCO, Feb. 17, 2026 (GLOBE NEWSWIRE) -- National shareholder rights law firm Hagens Berman is issuing an updated notice to investors in BellRing Brands, Inc. (NYSE: BRBR) regarding the March 23, 2026, lead plaintiff deadline accusing BellRing and certain of BellRing’s top executives of securities fraud. CLICK HERE TO SUBMIT YOUR BRBR LOSSES NOW The suit alleges Defendants misled investors about the true drivers of BellRing’s 2025 sales growth. The truth emerged over a series of disclosures revealin ...

Core Viewpoint - A class action lawsuit has been filed against Picard Medical, Inc. for alleged securities fraud and unlawful business practices [2][4]. Group 1: Lawsuit Details - The lawsuit involves allegations that Picard and certain officers and/or directors engaged in securities fraud [2]. - Investors have until April 3, 2026, to request to be appointed as Lead Plaintiff if they purchased Picard securities during the Class Period [2]. Group 2: Stock Price Surge - Picard's stock price increased from its IPO price of $4.00 per share to an all-time high of $13.68 per share before October 23, 2025, without any fundamental news to justify this rise [4]. - Investigations revealed that the stock price was artificially inflated through an illicit social-media promotion scheme, where impersonators made sensational claims to incite buying among retail investors [4]. Group 3: Law Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of fighting for victims of securities fraud and corporate misconduct [5]. - The firm has a track record of recovering multimillion-dollar damages for class members [5].

Core Viewpoint - A class action lawsuit has been filed against Masonite International Corporation, alleging securities fraud and unlawful business practices related to stock repurchases during a specific period [1][2]. Group 1: Lawsuit Details - The lawsuit claims that Masonite and its officers/directors engaged in securities fraud by failing to disclose multiple formal acquisition offers from Owens Corning while repurchasing its own stock at lower market prices [4]. - Investors who sold Masonite common stock during the Class Period have until April 7, 2026, to request to be appointed as Lead Plaintiff [2]. Group 2: Company Background - Pomerantz LLP, the firm handling the lawsuit, is recognized for its expertise in corporate, securities, and antitrust class litigation, having a history of recovering multimillion-dollar damages for victims of securities fraud [5].

Core Viewpoint - ICON Public Limited Company is under investigation for potential violations of federal securities laws, following a significant decline in shareholder value due to a revenue overstatement and a delay in financial results release [1][2]. Financial Performance and Market Reaction - The company's stock experienced a substantial single-day decline, erasing billions in shareholder value and marking one of the largest percentage drops in the Contract Research Organization (CRO) sector in recent years [2]. - Prior to the disclosure, ICON's stock was trading within a range that indicated investor confidence, with a full-year 2025 revenue guidance of $8.05 billion to $8.1 billion and adjusted EPS guidance of $13.00 to $13.20, figures affirmed by management as of October 23, 2025 [2][3]. Revenue Overstatement and Guidance Delay - ICON disclosed a preliminary revenue overstatement of under two percent per year for fiscal years 2023 and 2024, which led to the delay of its Q4 and full-year 2025 results [3]. - The CEO had previously assured investors that the company's performance was "broadly in line with expectations," while the CFO reported Q3 2025 revenue of $2.043 billion, reflecting a year-over-year increase of 0.6 percent [3]. Stock Buyback Activity - In the quarters leading up to the disclosure, ICON repurchased $750 million of its own stock and had a new $1 billion buyback authorization approved by its board, indicating prior confidence in its financial position [4]. - A filing on January 7, 2026, indicated that full-year 2026 guidance would be released alongside the delayed Q4 and full-year 2025 results, a timeline now affected by the announcement of the delay [4].

NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kyndryl Holdings, Inc. (“Kyndryl” or the “Company”) (NYSE: KD).   Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.  The class action concerns whether Kyndryl and certain of it ...

Core Viewpoint - A class action lawsuit has been filed against Mereo BioPharma Group plc, alleging securities fraud and unlawful business practices by the company and certain officers and/or directors [2]. Group 1: Lawsuit Details - Investors are encouraged to contact Pomerantz LLP for participation in the class action, with a deadline to apply as Lead Plaintiff by April 6, 2026 [2]. - A copy of the Complaint related to the class action can be accessed at Pomerantz's website [2]. Group 2: Company Performance and Stock Impact - On July 9, 2025, Mereo and Ultragenyx Pharmaceutical Inc. announced that the Phase 3 Orbit study was progressing towards a final analysis, leading to a significant drop in Mereo's ADR price by $1.25, or 42.52%, closing at $1.69 on July 10, 2025 [4]. - On December 29, 2025, Mereo reported that neither the Orbit nor the Cosmic Phase 3 studies achieved statistical significance, resulting in a drastic decline in ADR price by $2.02, or 87.7%, closing at $0.29 [5].

Core Viewpoint - Medpace Holdings, Inc. is under investigation for potential violations of federal securities laws following a significant drop in its stock price despite reporting strong Q4 earnings [1][2]. Financial Performance - Medpace reported Q4 revenue of $708.5 million and GAAP EPS of $4.67, both exceeding Wall Street consensus estimates [2]. - The company's shares fell approximately 10% by mid-day and closed down 15.9%, with a trading volume of about $10.2 million during the sell-off, indicating heightened trading activity [2]. Market Reaction - The decline in stock price was attributed to a bookings shortfall, which overshadowed the positive sales and profit figures [3]. - The book-to-bill ratio missed expectations, leading to a sharp decline in stock price and raising concerns about future demand [3]. Institutional Activity - Principal Financial Group reduced its stake in Medpace by 8.4% prior to the earnings release, while Representative David Taylor purchased shares shortly before [4]. - The timing of these transactions is relevant to the ongoing investigation [4]. Analyst Commentary - Analysts questioned management about the nature of booking deterioration during the Q4 earnings call, highlighting concerns over direct-fee growth and cancellation levels [5]. - Management acknowledged that the level of cancellations was the highest compared to the previous year, describing them as "broad-based" without providing clear reasons [5].